Vanguard Capital Management
CLDX icon

Vanguard Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Vanguard Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$129M Buy
3,464,831
+503,936
+17% +$16.3M ﹤0.01% 1422
2026
Q1 		$93.9M Buy
+2,960,895
New +$80.7M ﹤0.01% 1504

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Vanguard Capital Management's CLDX Position: Q2 2026 in Review

Vanguard Capital Management increased its Celldex Therapeutics (CLDX) stake by 17% in Q2 2026, buying an estimated $16.3M and bringing the position to 3,464,831 shares worth $129M. The position accounts for ﹤0.01% of the portfolio, ranked #1422.

Vanguard Capital Management first reported a position in CLDX in Q1 2026 and has held it in 2 quarters since. 252 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Vanguard Capital Management held 3,464,831 shares of Celldex Therapeutics worth $129M as of Q2 2026.
  • Vanguard Capital Management bought 503,936 Celldex Therapeutics shares in Q2 2026, an estimated $16.3M.
  • Celldex Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1422 holding.
  • Vanguard Capital Management first reported a position in Celldex Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 252 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.